HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells
- PMID: 12377730
- DOI: 10.1161/01.atv.0000034707.40046.02
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells
Abstract
Objective: Although HIV protease inhibitors have been successfully used against HIV infection, many metabolic side effects and premature cardiovascular diseases are often associated with this therapy. The mechanisms of these complications are not clear. In this study, we investigated the effect of the HIV protease inhibitor ritonavir on human endothelial cell cultures.
Methods and results: By using nonradioactive cell proliferation and cytotoxicity assays, human endothelial cells treated with ritonavir showed a significant decrease in cell viability and an increase in cytotoxicity in a time- and dose-dependent fashion. Mitochondrial DNA was also substantially damaged with ritonavir treatment by long polymerase chain reaction analysis. In contrast, ritonavir had a very limited effect on endothelial apoptosis, as assessed by analyses of DNA fragmentation and cellular caspase-3 activity.
Conclusions: These data demonstrate, for the first time, that the HIV protease inhibitor ritonavir at concentrations near clinical plasma levels is able to directly cause endothelial mitochondrial DNA damage and cell death mainly through necrosis pathways but not through apoptosis. This study suggests that HIV protease inhibitor-mediated endothelial injury may contribute to its cardiovascular complications.
Comment in
-
HIV therapies and atherosclerosis: answers or questions?Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1758-60. doi: 10.1161/01.atv.0000042080.46554.e6. Arterioscler Thromb Vasc Biol. 2002. PMID: 12426201 Review. No abstract available.
Similar articles
-
Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.Blood. 2002 May 15;99(10):3771-9. doi: 10.1182/blood.v99.10.3771. Blood. 2002. PMID: 11986235
-
The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.Br J Pharmacol. 2004 Dec;143(7):890-8. doi: 10.1038/sj.bjp.0706023. Epub 2004 Oct 25. Br J Pharmacol. 2004. PMID: 15504750 Free PMC article.
-
Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries.Med Sci Monit. 2011 Nov;17(11):BR312-318. doi: 10.12659/msm.882040. Med Sci Monit. 2011. PMID: 22037733 Free PMC article.
-
Atazanavir/ritonavir: a review of its use in HIV therapy.Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. Drugs Today (Barc). 2008. PMID: 18389089 Review.
-
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.Drugs. 2005;65(5):633-59. doi: 10.2165/00003495-200565050-00005. Drugs. 2005. PMID: 15748098 Review.
Cited by
-
Cardiovascular and Endothelial Disease in HIV Infection.Curr Infect Dis Rep. 2005 Jul;7(4):309-315. doi: 10.1007/s11908-005-0064-3. Curr Infect Dis Rep. 2005. PMID: 15963333
-
Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.AAPS J. 2016 Mar;18(2):362-71. doi: 10.1208/s12248-015-9838-1. Epub 2015 Nov 24. AAPS J. 2016. PMID: 26603889 Free PMC article.
-
Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets.Front Immunol. 2021 Mar 12;12:634386. doi: 10.3389/fimmu.2021.634386. eCollection 2021. Front Immunol. 2021. PMID: 33777022 Free PMC article. Review.
-
Reproductive toxicity of ritonavir in male: Insight into mouse sperm capacitation.Reprod Toxicol. 2022 Dec;114:1-6. doi: 10.1016/j.reprotox.2022.09.008. Epub 2022 Oct 2. Reprod Toxicol. 2022. PMID: 36198369 Free PMC article.
-
Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1.J Acquir Immune Defic Syndr. 2010 Oct;55(2):182-8. doi: 10.1097/QAI.0b013e3181e222c9. J Acquir Immune Defic Syndr. 2010. PMID: 20531209 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials